Evolus Secures $30M Revolving Credit Facility and Reports 11.6% Revenue Growth in 2025 Amid Rising Losses

summarizeSummary

Evolus reported increased 2025 revenues but wider net losses and higher cash burn, while securing a new $30M revolving credit facility and additional term loan tranches to bolster liquidity and support product launches.

check_boxKey Events

• New Revolving Credit Facility Secured

  On March 3, 2026, Evolus entered into a $30.0 million asset-based revolving credit facility with an uncommitted accordion feature of up to $10.0 million, maturing in three years. This provides crucial liquidity for operations.

• Amended Pharmakon Term Loans Provide Additional Capital

  In May 2025, the company amended its loan agreement with Pharmakon, securing up to $250.0 million. This included an initial $150.0 million tranche (with $25.0 million incremental borrowing) and two additional $50.0 million tranches available until December 31, 2026, further enhancing financial flexibility.

• Revenue Growth Amid Increased Net Losses

  Total net revenues for 2025 increased by 11.6% to $297.2 million from $266.3 million in 2024. However, the net loss widened to $51.6 million in 2025 from $50.4 million in 2024, and cash used in operating activities rose to $42.3 million from $18.0 million.

• Product Launches and Pipeline Advancement

  Evolysse Form and Smooth injectable HA gels were launched in the United States in April 2025. The company anticipates European launch of all four Evolysse products in Q2 2026 and US approvals for Evolysse Sculpt (H2 2026) and Evolysse Lips (2027).

auto_awesomeAnalysis

Evolus, Inc. reported an 11.6% increase in total net revenues to $297.2 million for 2025, driven by the launch of Evolysse products. However, the company's net loss widened to $51.6 million, and cash used in operating activities significantly increased to $42.3 million. Critically, the company secured a new $30.0 million asset-based revolving credit facility on March 3, 2026, with an additional $10.0 million accordion feature, and amended its Pharmakon Term Loans in May 2025 to include $25.0 million in incremental borrowing and two additional $50.0 million tranches. These financing activities are essential for extending the company's liquidity and funding ongoing commercialization efforts and product development, especially given the shift to a stockholders' deficit of $23.1 million. Continued progress in the Evolysse product pipeline, with anticipated US approvals in 2026 and 2027, is vital for future profitability.